Top Markets
#1 Resolv wstUSR Resolv wstUSR +114.61%
#2 Luxxcoin Luxxcoin +45.05%
#3 ResearchCoin ResearchCoin +21.75%
#4 Reactive Network Reactive Network +20.82%
#5 Layer3 Layer3 +20.58%
#6 Orderly Network Orderly Network +16.63%
#7 Aria.AI Aria.AI +12.89%
#8 Bitgert Bitgert +10.56%
#9 Lisk Bridged wstETH (Lisk) Lisk Bridged wstETH (Lisk) +9.40%
#10 KAITO KAITO +9.17%
Coin of the day
Resolv wstUSR Resolv wstUSR
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
CSL Limited CSL Limited

CSL Limited

CSL
Classificação em ações #432
CSL Limited researches, develops, manufactures, markets, and distributes... CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Preço da ação
$99.32
Valor de mercado
$48.20B
Variação (1 dia)
0.98%
Variação (1 ano)
-32.14%
País
AU
Negociar CSL Limited (CSL)

Categoria

Healthcare
Lucros da CSL Limited (CSL)
Lucros em Dec 2025 TTM: $1.61B
De acordo com os últimos relatórios financeiros da CSL Limited, os ganhos atuais da empresa são de $1.61B. Em 2024, a empresa teve ganhos de $3.38B, um aumento em relação a aos ganhos de 2023, que foram de $2.66B. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da CSL Limited de 2000 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $1.61B -56.65%
2025 $3.72B 10.34%
2024 $3.38B 26.74%
2023 $2.66B -4.19%
2022 $2.78B -6.80%
2021 $2.98B 15.92%
2020 $2.57B 9.89%
2019 $2.34B 2.63%
2018 $2.28B 35.00%
2017 $1.69B 8.61%
2016 $1.56B -9.22%
2015 $1.71B 6.84%
2014 $1.60B 19.64%
2013 $1.34B 5.36%
2012 $1.27B -7.31%
2011 $1.37B 38.29%
2010 $992.87M 11.00%
2009 $894.45M 2.37%
2008 $873.74M 56.73%
2007 $557.47M 493.43%
2006 $93.94M -74.77%
2005 $372.39M 201.20%
2004 $123.64M 168.99%
2003 $45.96M -7.38%
2002 $49.63M -8.38%
2001 $54.17M 88.04%
2000 $28.81M 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B 1,170.24%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B 187.63%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B 224.03%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B 32.42%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -10.11%
NL